• Illumina Acquires SomaLogic, Sanofi’s New CEO, Parse Bioscience’s New Product Line

    Bio-IT World | Illumina completes its acquisition of SomaLogic; Sanofi appoints Belén Garijo as chief executive officer; Parse Biosciences launches the new Evercode Whole Transcriptome v4 product line; and more.

    Feb 26, 2026

  • Follow the Money: International Expansion for Cell Therapies, BPZE1 Pertussis Vaccine, Next-Gen AI De Novo Antibody Design

    Bio-IT World | Cellares expands across different countries to commercially launch and manufacture cell therapies; ILiAD Biotechnologies advances their next generation pertussis vaccine candidate, BPZE1; Galux develops next-gen AI that goes beyond binder design to incorporate functional activity and developability; and more.

    Feb 25, 2026

  • Predicting When Alzheimer’s Symptoms Will Emerge

    Bio-IT World | The Foundation for the National Institutes of Health (FNIH), Washington University in St. Louis, the University of California San Francisco, the University of Wisconsin-Madison, and more have published the results of a study in Nature Medicine that determined a blood-based biomarker model that estimates not only the likelihood of Alzheimer’s disease but also when symptoms are likely to emerge.

    Feb 24, 2026

  • Welcome to the Next Frontier in Drug Discovery: The Surfaceome

    Bio-IT World | The scientific community has made tremendous progress in the ability to identify and predict protein targets, advancing from bulk cellular analysis approaches to technologies with resolutions that now approach subcellular. Despite these achievements, fundamental questions in drug discovery remain difficult to answer: has the ideal protein target been identified, and is it easily accessible to intervention to accelerate the development pipeline and reduce candidate attrition?

    Feb 20, 2026

  • Deloitte Survey Reveals Sharp Divide for This Year’s Outlook

    Bio-IT World | During the Clinical Trial Venture, Innovation, and Partnering event at this year’s SCOPE, Deloitte Consulting’s 2026 Life Sciences Executive Outlook revealed in a presentation that 75% of 280 surveyed C-suite executives across pharma and medtech expressed a positive or cautiously positive outlook. Yet beneath that headline lies a sharp transatlantic divide.

    Feb 19, 2026

  • Red Light Therapy Shows Promise for Treating Brain Injuries

    Bio-IT World | Repetitive head acceleration events (RHAEs) are repeated impacts that rapidly move the head and can cause concussions and brain damage. Yet current interventions remain reactive, focused on rest and symptom management after injury, rather than preventing microscopic damage that accumulates over time. A new study from the University of Utah Health has found an unconventional approach: photobiomodulation (PBM), or red light therapy.

    Feb 17, 2026

  • New AI Approach Weighs Data ‘Temperature’ to Improve Prediction Accuracy

    Bio-IT World | Anything that can be defined as a system—a mixed-bag list that includes physical materials like silicon and graphene as well as patient-specific implantable devices and the human brain—are subject to the law of entropy, meaning its disorder irreversibly increases over time if left alone. It turns out that this fundamental concept has a more comprehensive approach, dubbed zentropy by its creators at Penn State.

    Feb 12, 2026

  • Redefining Hypertension Treatment with Brain’s Control Circuit

    Bio-IT World | For decades, the industry’s approach to treating high blood pressure has centered on various organs—the heart, kidneys, and blood vessels. A new study suggests that this strategy may address downstream effects rather than the root cause. The primary driver of hypertension in a majority of patients may reside in the brain.

    Feb 11, 2026